| Description | Succinobucol (Probucol monosuccinate) is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease. |
| In vitro | In rabbit whole blood, Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. |
| In vivo | 在肺转移性乳腺癌小鼠中，通过尾部注射给予Succinobucol（40 mg/kg）显著降低了平均转移结节数。而在大鼠中，通过静脉注射Succinobucol（50、100、150 mg/kg）对心率或MAP均无显著影响。 |
| Cell experiments | In the metastatic 4T1 breast cancer cells, Succinobucol, SCB and the PCD polymer (equivalent concentration to SCB) are respectively added to each well with SCB concentrations ranging from 4 ng/mL to 40 μg/mL. |
| Animal experiments | Mice, injected 4T1-luc cells, are treated with Succinobucol (40 mg/kg) by tail injection every three days. |
| Synonyms | Probucol monosuccinate, AGI-1067 |
| molecular weight | 616.91 |
| Molecular formula | C35H52O5S2 |
| CAS | 216167-82-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (72.94 mM) |
| References | 1. Houston SA, et al. An investigation of the antiplatelet effects of succinobucol (AGI-1067). Platelets. 2017 May;28(3):295-300 2. Colle D, et al. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-95. 3. Dan Z, et al. A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics. 2016 Jan 25;6(3):435-45. |